血清钾、红细胞和血红蛋白对前列腺癌内分泌治疗后疾病无进展生存期的预测价值  

Predictive value of serum potassium,red blood cell count and hemoglobin for disease progression-free survival of prostate cancer after endocrine therapy

作　　者：张悦 任圣举 杜然然[2,3] 张腾飞[1,4] ZHANG Yue;REN Shengju;DU Ranran;ZHANG Tengfei(Department of Oncology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China;Institute of Medical Informution,Chinese Academy of Medical Sciences,Beijing 100005,China;Institute of Medical Information,Peking Union Medical College,Beijing 100005,China;Medical School,Huanghe University of Science and Technology,Zhengzhou 450015,China)

机构地区：[1]郑州大学第一附属医院肿瘤科,河南郑州450052 [2]中国医学科学院医学信息研究所,北京100005 [3]北京协和医学院医学信息研究所,北京100005 [4]黄河科技学院医学院,河南郑州450015

出　　处：《肿瘤基础与临床》2024年第5期518-522,共5页journal of basic and clinical oncology

基　　金：河南省自然科学基金面上项目(212300410398);中原英才计划青年拔尖人才项目(ZYQR201810149);河南省中青年卫生健康科技创新杰出青年人才培养项目(YXKC2022039)。

摘　　要：目的探索治疗前血清钾、红细胞和血红蛋白对前列腺癌患者内分泌治疗后疾病无进展生存期(PFS)的预测作用。方法收集2013年1月至2017年12月郑州大学第一附属医院收治的190例前列腺癌患者的临床资料。提取可能影响前列腺癌预后的因素,包括患者年龄、前列腺癌TNM分期、前列腺癌Gleason评分、内分泌治疗的药物类型及治疗前空腹血清钾浓度、红细胞计数、血红蛋白水平、碱性磷酸酶(ALP)水平、白细胞计数和血小板计数6个血液学指标。结果190例患者中位PFS为40.8个月。Kaplan-Meier生存分析显示,TNM分期(P=0.046)、空腹血清钾浓度(P=0.014)、红细胞计数(P=0.029)、血红蛋白水平(P=0.018)和ALP(P=0.008)与前列腺癌患者PFS有关。血红蛋白水平与红细胞计数具有显著正相关性(r=0.869、P<0.001)。将TNM分期、空腹血清钾浓度、红细胞计数和ALP纳入COX比例风险回归模型进行多因素生存分析,结果表明,TNM分期(P=0.007)、空腹血清钾浓度(P=0.006)和红细胞计数(P=0.018)是预测PFS的独立预后因素。结论TNM分期、治疗前空腹血清钾浓度和红细胞计数是预测前列腺癌患者内分泌治疗后PFS的独立预后因素,TNM分期早、空腹血清钾浓度正常范围内较低、红细胞计数正常的前列腺癌患者比TNM分期晚、空腹血清钾浓度正常范围内较高、红细胞计数低的患者拥有更长的PFS。Objective To investigate the predictive value of serum potassium,red blood cell count and hemoglobin before treatment for progression-free survival(PFS)of prostate cancer patients after endocrine therapy.Methods The clinical data of 190 patients with prostate cancer admitted to the First Affiliated Hospital of Zhengzhou University from January 2013 to December 2017 were collected.The factors that may affect the prognosis of prostate cancer were extracted,including age of patients,TNM stage of prostate cancer,Gleason score of prostate cancer,type of endocrine therapy drugs.And the six hematological indicators before treatment were extracted,including fasting serum potassium concentration,red blood cell count,hemoglobin concentration,alkaline phosphatase concentration(ALP),white blood cell count and platelets count.Results The median PFS of 190 patients was 40.8 months.Kaplan-Meier survival analysis showed that TNM stage(P=0.046),fasting serum potassium concentration(P=0.014),red blood cell count(P=0.029),hemoglobin concentration(P=0.018)and ALP(P=0.008)were associated with PFS in the prostate cancer patients.There was a significant positive correlation between hemoglobin concentration and red blood cell count(r=0.869,P<0.001).TNM stage,fasting serum potassium concentration,red blood cell count and ALP were included in COX proportional risk regression model for multivariate survival analysis.The results showed that TNM stage(P=0.007),fasting serum potassium concentration(P=0.006)and red blood cell count(P=0.018)were independent prognostic factors for predicting PFS.Conclusion TNM staging,fasting serum potassium concentration and red blood cell count before treatment are the independent prognostic factors for PFS of prostate cancer patients after endocrine therapy.Prostate cancer patients with earlier TNM stage,lower fasting serum potassium concentration in the normal range or normal red blood cell count had longer PFS than patients with later TNM stage,higher fasting serum potassium concentration in the normal rang

关 键 词：前列腺癌 空腹血清钾浓度 红细胞计数 疾病无进展生存期 

分 类 号：R737.25[医药卫生—肿瘤]